YAKUGAKU ZASSHI
The Pharmaceutical Society of Japan, established in 1880, is one of Japan’s oldest and most distinguished academic societies. The Society currently has around 18,000 members. It publishes three monthly scientific journals. Chemical and Pharmaceutical Bulletin (Chem. Pharm. Bull.) began publication in 1953 as Pharmaceutical Bulletin. It covers chemistry fields in the pharmaceutical and health sciences. Biological and Pharmaceutical Bulletin (Biol. Pharm. Bull.) began publication in 1978 as the Journal of Pharmacobio-Dynamics. It covers various biological topics in the pharmaceutical and health sciences. A fourth Society journal, the Journal of Health Science, was merged with Biol. Pharm. Bull. in 2012. Yakugaku Zasshi (Japanese for “Pharmaceutical Science Journal”) has the longest history, with publication beginning in 1881. Yakugaku Zasshi is published mostly in Japanese, except for some articles related to clinical pharmacy and pharmaceutical education, which are published in English.
The main aim of the Society’s journals is to advance the pharmaceutical sciences with research reports, information exchange, and high-quality discussion. The average review time for articles submitted to the journals is around one month for first decision. The complete texts of all of the Society’s journals can be freely accessed through J-STAGE. The Society’s editorial committee hopes that the content of its journals will be useful to your research, and also invites you to submit your own work to the journals.

Chairman of Committee
Sumio Ohtsuki
Faculty of Life Sciences, Kumamoto University
Read more
17,333 registered articles
(updated on July 10, 2020)
Online ISSN : 1347-5231
Print ISSN : 0031-6903
ISSN-L : 0031-6903
0.286
2018 Journal Impact Factor (JIF)
JOURNALS PEER REVIEWED FREE ACCESS ADVANCE PUBLICATION
Scopus Pubmed
Featured article
Volume 140 (2020) Issue 7 Pages 923-928
Liver Injury Risk Factors in Amyotrophic Lateral Sclerosis Patients Treated with Riluzole Read more
Editor’s picks

Riluzole is a drug used to manage amyotrophic lateral sclerosis (ALS). Previous reports indicate a high incidence of liver injury in patients taking riluzole. Therefore, this study aimed to determine the risk factors for liver injury among patients who were prescribed riluzole from 1999 to 2015. As a result, concurrent use of CYP1A2 inhibitors, and history of smoking are independent risk factors associated with the development of liver injury in ALS patients who are prescribed riluzole.

View all featured articles
View all articles in Current issue
Most viewed articles Jun.2020
Share this page
Select past volume & issue
feedback
Top